TARSUS PHARMACEUTICALS, INC. Marketable Securities, Unrealized Gain (Loss)
TARSUS PHARMACEUTICALS, INC. (TARS) reported Marketable Securities, Unrealized Gain (Loss) of $10.00 thousand for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2022-11-09
- TARSUS PHARMACEUTICALS, INC. marketable securities, unrealized gain (loss) for the quarter ending 2022-09-30 was $10.00K.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month |
|---|---|
| 2022-09-30 | $10.00K 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |